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here remains a critical need to better understand
the underlying disease mechanisms responsible
for diabetes complications in order to develop
new and improved therapeutic strategies for
these chronic conditions. These complications are broadly
classiﬁed as microvascular, including neuropathy, nephrop-
athy, and retinopathy, or macrovascular, including car-
diovascular and peripheral vascular disease. The risk for
developing complications is inﬂuenced by many factors
including duration of diabetes and genetic factors. Current
treatments have resulted in only a partial reduction in this
risk, and the management of these conditions remains
a major unmet need for those with diabetes. New insights
have come from an unlikely ally, the worm C. elegans,i n
which research has identiﬁed a novel family of endoge-
nous, small (;22 nucleotides), single stranded, noncoding
RNA molecules known as microRNAs (miRNAs) as de-
velopmental regulators (1,2). These molecules, only iden-
tiﬁed in humans in the last decade, modulate physiological
and pathological processes by the posttranscriptional in-
hibition of gene expression (3). Many excellent reviews
have been written dealing with biogenesis (4) through to
their role in development and disease (5), although this
work has generally focused on cancer and infection rather
than diabetes and its complications (6).
The effect of miRNAs is via the incomplete binding of
the “seed sequence” at the 59 end of the miRNA to the
complementary target site in the 39 untranslated region
(UTR) of the messenger RNA. Each miRNA species can
inhibit the expression of many genes, while each mRNA
can be potentially targeted by several miRNAs. Recent
studies have demonstrated clear links between altered
miRNA expression and certain diabetes complications, as
described later in this article. These ﬁndings further high-
light the complex nature of diabetes and the huge challenge
in better understanding the various vascular complications
associated with this disorder. Here we discuss some re-
cent studies demonstrating the role of miRNAs in diabetes
complications and at sites where complications occur, with
the anticipation that these studies are likely to inﬂuence
the treatment, diagnosis, and management of complica-
tions. We also explore the huge clinical challenge before
us in attempting the targeted modulation of these rather
promiscuous molecules in speciﬁc tissues in order to
achieve better therapeutic outcomes.
miRNAS IN DIABETES COMPLICATIONS
There is a wealth of evidence on the diverse role of miRNAs
in many biological processes, including proliferation,
differentiation, apoptosis, and development. The list of
diseases in which dysregulation of miRNAs has been im-
plicated is constantly growing. Compared with cancer, far
less is known about the role of miRNAs in diabetes and its
complications. Several miRNAs have been identiﬁed as
having a physiological role in tissues in which diabetes
complications occur. Whether these miRNAs are involved
in the damage that occurs in diabetes is yet to be estab-
lished. The association between altered miRNA expression
and the development and progression of the various di-
abetes complications implicates certain miRNAs in the
development of diabetes-related injury in the heart, kid-
ney, peripheral nerves, and retina. Given that each miRNA
has the potential to regulate multiple genes, dysregulation
of miRNAs would be certain to have impact on many bi-
ological processes that are of direct relevance to diabetes
complications. As tempting as it is to have a blinkered
approach to our favorite miRNA and target gene, it is naïve
to ignore the incredible complexity of miRNA regulation
and the depth of the downstream maze of targets, both
direct and indirect. This complexity is highlighted later in
this article, demonstrating how both increased and de-
creased expression of certain miRNAs are associated with
diabetes complications. A summary of the miRNAs rele-
vant to diabetes complications is found in Table 1.
CAN WE IDENTIFY PATIENTS AT RISK FOR DEVELOPING
COMPLICATIONS?
Gene proﬁling technology has been used with a view to
improve disease diagnosis and prognosis, especially in the
area of cancer research. Over a third of diabetes patients
develop serious complications. Can we use miRNA proﬁling
to identify patients that go on to develop complications?
One study observed increased expression of several
miRNAs in the diabetic GK rat model, including increased
expression of the miR-29 family in muscle, fat, and liver,
correlating with insulin resistance (7). Another study pro-
ﬁled miRNA expression in skeletal muscle of the sponta-
neous diabetic GK rat and observed the downregulation of
seven and overexpression of two miRNAs, with miR-24
showing the highest fold change (8). Kloting et al. (9) ex-
amined miRNA expression proﬁles in omental and sub-
cutaneous fat deposits in control subjects and newly
diagnosed diabetic patients. Interestingly, similar expres-
sion patterns were observed in both fat deposits for each
patient, but differences were observed between patients
based on parameters of obesity and metabolism. Zampetaki
et al. (10) proﬁled miRNAs in the plasma of 800 patients
in a prospective study of type 2 diabetic patients and
established a diabetes signature based on ten miRNAs.
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PERSPECTIVES IN DIABETESThey made similar observations in hyperglycemic leptin
obese mice. Interestingly, they observed the decreased ex-
pression of six miRNAs several years prior to the onset of
type 2 diabetes. This decreased expression correlated with
subclinical peripheral artery disease, suggesting that such
a signature may be used to identify high risk individuals
prone to getting diabetes complications. Studies such as
this are very important and have the potential to make im-
portant contributions toward earlier identiﬁcation of high
risk individuals and better management of the early disease.
Further advances in proﬁling techniques using readily ac-
cessible biological ﬂuids will lead to good advances in this
important area.
The identiﬁcation of single nucleotide polymorphisms
(SNPs) in certain miRNAs (11) and, in particular, in miR-29
in type 1 diabetes is interesting given the potential role of
miR-29 in renal ﬁbrosis (see below). Whether these SNPs
alter the regulation of miRNA transcription/stability and
whether they are relevant on a broader scale in diabetes
complications will need to be clariﬁed.
A real advance in this area would be the conﬁrmation of
the previously identiﬁed miRNA signature (10) and further
development to identify prediabetes in patients before they
develop overt disease. Equally important would be the
identiﬁcation of a signature for the subset of diabetes
patients that go on to develop complications.
miRNAS IN DIABETIC NEPHROPATHY
Diabetic nephropathy (DN) is the leading cause of kidney
failure, affecting the glomerulus and ultimately leading to
progressive kidney scarring. Fibrosis is characterized by
the excess accumulation and deposition of extracellular
matrix (ECM), the predominant proteins being collagens,
but also ﬁbronectin, ﬁbrillin and elastin. ECM is synthe-
sized by many cell types but the principal effector cells in
the kidney are myoﬁbroblasts, arising from renal tubular
cells via epithelial to mesenchymal transition (EMT) and
endothelial cells via endo-MT, bone marrow derived cells
and resident interstitial ﬁbroblasts (12). Blockade of spe-
ciﬁc steps of EMT dramatically reduces ﬁbrotic lesions
in models of kidney ﬁbrosis, including diabetes, highlight-
ing the role of some aspects of the EMT pathway in ne-
phropathy (12).
Recent attention has turned to the role of miRNAs in
renal disease where Dicer knockout experiments have
established the general importance of miRNA in normal
renal development and function (13). Other studies have
provided evidence linking prosclerotic factors and miRNAs
to ﬁbrosis (14–19) and have provided the much needed
impetus in this area with the promise of new approaches
for the treatment of ﬁbrosis. Figure 1 shows the main
miRNAs that have been reported to play a role in diabetic
nephropathy and are outlined below.
miR-192. The role of miR-192 remains controversial and
highlights the complex nature of miRNA research. Kato
et al. (16) observed increased renal expression of miR-192
in streptozotocin (STZ)-induced diabetes and in the db/db
mouse and demonstrated that tranforming growth factor
(TGF-b1) upregulated miR-192 in mesangial cells (MCs).
miR-192 repressed the translation of ZEB2, a transcrip-
tional repressor that binds to the E-box in the collagen 1a2
(col1a2) gene (16). They proposed that miR-192 repressed
ZEB2 and resulted in increased col1a2 expression in vitro
and contributed to increased collagen deposition in vivo.
These data suggest a role for miR-192 in the development
of the matrix accumulation observed in DN. Interestingly,
miR-192 and a number of other miRNAs have also been
correlated with disease severity and progression in patients
with IgA nephropathy (20) and hypertensive nephro-
sclerosis (21), suggesting that miR-192 may also play
a role in other forms of renal disease. More recently, a
tight association was observed between upregulation of
miR-192 in the ﬁbrotic kidney and TGF-b1/Smad signaling
TABLE 1
Diabetes complications: miRNAs and their targets
Complication Known targets Reference
Diabetic nephropathy
miR-21 PTEN (29) unpublished*
miR-29 family Collagens (25) unpublished*
miR-192 ZEB2, Col 1 (16,18,22,23)
miR-93 VEGF (34)
miR-200 family ZEB1, ZEB2, TGF-b2 (18,19)
miR-216a YB-1, PTEN (15,26)
miR-377 PAK1, MnSOD (30)
Retinopathy
miR-93, miR-200,
and miR-29
families?
VEGF (34) indirect†
Atherosclerosis
miR-16 COX-2 (39) indirect†
miR-503? CCNE1, cdc25A (40)
Heart
miR-21 SPRY1 (50,51)
miR-29 Collagens (17)
miR-30? CTGF (48) indirect†
miR-1/133 ERG, RhoA, Cdc42,
WHSC2, HCN1,
and HCN4
(44–47)
miR-320 VEGF, FGF, IGF-1,
and IGF-1R
(46)
*H.Y.L., unpublished data.†Inferred from the reference.
FIG. 1. Summarized here are the miRNAs known to have a role in the
development and progression of diabetic nephropathy. A number of
miRNAs have been identiﬁed as contributing to diabetes complications
and in particular in diabetic nephropathy. Several of the miRNAs shown
here have been directly connected to this disease via speciﬁc targets,
while the speciﬁc details of others are yet to be clearly established. In
the case of miR-192, the dual published roles are shown.
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expression in the rat subtotal nephrectomy model. Im-
portantly, this study also revealed the regulatory mecha-
nisms by which TGF-b1 regulates miR-192 expression via
the Smad3 but not the Smad2 signaling pathway. Indeed,
overexpression of the miR-192 mimic promoted whereas
knockdown of miR-192 inhibited TGF-b1–induced colla-
gen expression.
In contrast to the above, other reports suggest the re-
lationship between miR-192 and renal ﬁbrosis may be
more complicated. Krupa et al. (23) identiﬁed two miRNAs
in human renal biopsies, the expression of which differed
by more than twofold between progressors and non-
progressors with respect to DN, the greatest change oc-
curring in miR-192 which was signiﬁcantly lower in patients
with advanced DN, correlating with tubulointerstitial ﬁbro-
sis and low glomerular ﬁltration rate. They also reported, in
contrast to the Kato et al. (16) study in MCs, that TGF-b1
decreased expression of miR-192 in cultured proximal tu-
bular cells (PTCs) (23). These investigators concluded that
a decrease in miR-192 is associated with increased renal
ﬁbrosis in vivo. Our own work in this area conﬁrms the view
that loss of miR-192 is associated with renal ﬁbrosis (18).
TGF-b1 treatment induced decreased expression of miR-192
and miR-215, which target ZEB2, along with changes typ-
ical of EMT, including increased ﬁbrogenesis and decreased
E-cadherin expression in PTCs. Interestingly, connective
tissue growth factor (CTGF) treatment also resulted in
ﬁbrogenesis but caused the induction of miR-192/215 and,
consequently, decreased ZEB2 and increased E-cadherin.
Ectopic expression of miR-192/215 resulted in increased
E-cadherin by targeting ZEB2, but had no impact on ﬁbro-
genesis. Thus, our work demonstrates a clear link between
miRNA-192/215 and ZEB2 in TGF-b1/CTGF-mediated changes
in E-cadherin expression, independent of ﬁbrosis (18).
The contrasting ﬁndings above highlight the complex
nature of miRNA research. Some of the differences may
relate to models and/or experimental conditions; however,
one often overlooked explanation is that some effects of
miRNAs and inhibitors are likely to be indirect in nature.
Our understanding of how miRNAs function is continually
evolving, with recent evidence demonstrating that miRNAs
can also regulate gene expression via deadenylation and
altering message stability, and by modulation of transcrip-
tion. Bioinformatics using pathway analysis will be needed
to better understand the cross-talk between factors that
drive many downstream processes and how those processes
ultimately impact the expression of individual genes.
The miR-200 family. The next family of miRNAs to be-
come a hot area of research in DN was the miR-200 family
with researchers quickly making the obvious link between
miR-200 and EMT. The pioneering work of Gregory et al.
(14) established the role of the miR-200 family as regu-
lators of the epithelial phenotype primarily by targeting
ZEB1/2, the transcriptional repressors of E-cadherin. These
observations established the important link between miRNA,
the prosclerotic TGF-b pathways, and EMT in ﬁbrosis. Both
TGF-b1 and TGF-b2 decreased the expression of the miR-200
family in renal cells (18,19). This decrease is accompanied
by an increase in expression of TGF-b2, the 39 UTR of this
prosclerotic cytokine being a target for miR-200a. This work
demonstrated a feedback loop by which increased TGF-b2
causes decreased miR-200a, which in turn relieves repression
of TGF-b2 expression, and hence promotes ﬁbrosis. Inter-
estingly, we also observed that miR-200a could decrease
Smad3 activity and attenuate TGF-b–induced ECM protein
synthesis, however whether this effect was direct was not
determined (19). Identifying and deciphering the complex
regulation of multiple targets and pathways impacted on
by each miRNA remains a challenge, both in terms of un-
derstanding and using this knowledge for clinical beneﬁt.
miR-29. Recent reports have linked miR-29 to ﬁbrosis,
especially in renal disease. miR-29a has been shown to be
important in the regulation of a number of collagens in
a model of hypertensive renal disease (24) and miR-29b in
the kidneys of salt-sensitive rats (24). Qin et al. (25) found
that miR-29 was downregulated in the ﬁbrotic kidney of
obstructive nephropathy and was negatively regulated by
TGF-b1 via the Smad3, but not the Smad2, signaling path-
way. Indeed, Smad3 physically bound the miR-29 promoter
and repressed miR-29 expression, thereby promoting col-
lagen matrix expression. Our own unpublished work has
also demonstrated signiﬁcantly decreased expression of
miR-29 family members in STZ-induced diabetic mice and
rats. More importantly, the ﬁnding of inhibition of progressive
renal ﬁbrosis in obstructive nephropathy by ultrasound-
microbubble–mediated miR-29b gene transfer demonstrated
that miR-29 may be a novel therapeutic molecule for renal
ﬁbrosis (25).
miR-216a. Kato et al. (26) have proposed miR-216a as
another potential contributor to DN. miR-216a was up-
regulated by TGF-b1 in MCs, resulting in increased col1a2
expression. This involved an interaction between the
col1a2 E-box and a complex of a number of molecules,
one of which was shown to be regulated by the RNA-
binding protein YB-1 (26). Kato et al. (26) postulated that
increased miR-216a regulates the expression of Col1a2 by
targeting YB-1 expression. Fraser et al. (27) demonstrated
that YB-1 is a regulator of TGF-b1 mRNA translation in
PTCs. Therefore, repression of YB-1 by miR-216a may also
signiﬁcantly contribute to ﬁbrogenesis through increased
TGF-b1. miR-216a and miR-217 have also been implicated
by targeting the repression of the phosphatase and tensin
homolog (PTEN) tumor suppressor gene, which results in
activation of AKT, a key driver of DN (15,28). This example
demonstrates the indirect and complex pathways by which
miRNAs can affect important processes in cell physiology
and biochemistry. One needs to add to this scenario the
promiscuous nature of miRNAs and the multiple miRNA
regulatory sites found on mRNAs to fully appreciate the
tremendous complexity of miRNA regulation of cellular
processes and disease.
miR-21. Decreased expression of miR-21 has been ob-
served early in DN, while ectopic expression of miR-21
inhibits MC proliferation under conditions of elevated
glucose (29). Ectopic expression in vivo resulted in de-
creased albuminuria in diabetic db/db mice (29). PTEN is
a target of and is decreased by miR-21, leading to in-
creased p-Akt in MCs and db/db mice. How the opposing
actions of decreased miR-21 (29) and increased miR-216a
(15,28), which both target PTEN, contribute to renal ﬁ-
brosis will need to be clariﬁed. The relative contribution of
each miRNA and the overall balance of miRNA expression
needs to be established in order to make sense of the
published data. Once again the contrasting experimental
ﬁndings highlight the complex role of miRNAs in disease.
We have recently observed that miR-21 expression was
signiﬁcantly upregulated in a mouse model of obstructive
nephropathy and was also regulated by the TGF-b/Smad3
signaling pathway in vivo and in vitro. The ﬁndings that
overexpression of miR-21 enhanced but that knockdown
of miR-21 blocked renal ﬁbrosis in vitro in response to
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phropathy suggests that miR-21 may also be an attractive
target for the prevention of renal ﬁbrosis under certain
conditions (unpublished data, P.K., B.W., R.M.C., and H.Y.L.).
miR-377. miR-377 was found to be elevated in spontane-
ous and STZ-induced models of DN (30). This study also
found miR-377 to be elevated in MCs following TGF-b1
treatment in high glucose conditions. Ectopic expression
of miR-377 in MCs resulted in increased ﬁbronectin expres-
sion as well as other genes that contribute to DN. Fibro-
nectin is not a direct target of miR-377, however miR-377
targets the expression of PAK1 and MnSOD, which indirectly
lead to elevated ﬁbronectin expression (30) and hence con-
tribute to DN. The overall contribution of miR-377 to DN
remains to be determined.
miR-93. Vascular endothelial growth factor (VEGF) has
been implicated in microvascular complications and is
considered to be a signiﬁcant player in diabetic retinopa-
thy and nephropathy where it is often upregulated (31,32).
Anti-VEGF treatment in animal models of diabetes showed
signiﬁcant improvement in kidney function (33). Long et al.
(34) recently identiﬁed miR-93 to be a “signature miRNA”
in hyperglycemic conditions both in vitro and in vivo,
and that VEGF-A was a target of miR-93. They reported
that hyperglycemia led to reduced miR-93 expression by
downregulating the promoter of the host gene MCM7 in
which miR-93 resides. The authors demonstrated that
increased miR-93 expression prevented the hyperglycemia-
induced expression of VEGF and its downstream signal-
ing. Conversely, targeting miR-93 in vivo with morpholino
oligomers induced VEGF expression (34).
DIABETIC RETINOPATHY
There are currently no studies linking miRNAs to diabetic
retinopathy (DR). It is generally believed that the hyper-
glycemic environment and elevated expression of several
growth factors are key mediators of DR. Of particular
importance is VEGF which has been shown to be elevated
in DR, resulting in pathogenic changes to the retinal struc-
ture, including neovascularization (32,35). Anti-VEGF ther-
apy appears to be promising, although the ﬁndings of large
trials are awaited to conﬁrm these early ﬁndings (36). Given
that VEGF is a predicted target of several miRNAs, including
t h o s et h a th a v ea l r e a d yb e e ni m plicated in other diabetes
complications (miR-200b/c, miR-29a/b/c, and miR-93), it
would be interesting to determine whether these miRNAs
may also be relevant in DR.
DIABETIC ATHEROSCLEROSIS
Advanced glycation end products (AGEs) act through the
receptor for AGEs (RAGE), activating inﬂammatory path-
ways. One of the endogenous physiological ligands of RAGE
is S100b, a member of the S100/calgranulin family (37),
and interaction of these ligands with RAGE is critical in
inﬂammation, including in diabetic atherosclerosis (38).
Shanmugam et al. (39) recently reported that expression
and binding of miR-16 to the COX-2 mRNA 39UTR in THP-1
monocytic cells was inhibited by the binding of S100b to
the RAGE receptor. In this case, the binding of S100b
displaced the nuclear heterogeneous nuclear ribonucleo-
protein K such that it translocates to the cytoplasm, to in-
teract with the COX-2 39UTR, to interfere with the binding
of miR-16. The complexity of such interactions serves to
remind us of the various layers of regulation that need to
be understood before our knowledge of miRNAs can be
used to produce better therapeutic outcomes in diabetes
complications. More recent work has identiﬁed increased
miR-503 as an important contributor to diabetes-induced
impairment of endothelial function and angiogenesis by
directly targeting CCNE1 and cdc25A (40). Whether this
miRNA plays a role in diabetic atherosclerosis remains to
be established.
HEART
miR-133. Diabetic cardiomyopathy, although not fully
characterized, typically displays hypertrophy of the heart
and contractile dysfunction, which eventually leads to heart
failure. Much attention has focused on miR-133, since it
is abundantly expressed in heart and is a regulator of
myogenesis (41). In the diabetic context, miR-133 has
been postulated to be a signiﬁcant contributor to cardiac
pathology. The role of miR-133 in the diabetic heart is very
interesting as it appears to have a dual role depending on
whether expression is increased or decreased. How the
balance between the two opposing actions of miR-133
works in diabetes remains an intriguing mystery.
Elevated cardiac expression of miR-133 is dependent on
the serum response factor (SRF), which is elevated in the
diabetic heart (42). Knockdown of SRF prevents increased
expression of miR-133 (42), and cardiac speciﬁc dysregu-
lation of SRF expression results in cardiac hypertrophy
and other cardiac pathologies similar to those observed
in the early stages of congestive heart failure. One con-
sequence of increased cardiac expression of miR-133 is a
perturbation to cardiac conductivity (42). An important
electrical disturbance that is seen in diabetic patients is
the prolongation of the QT interval, which represents the
duration for ventricular depolarization and repolarization
of myocytes. This cycle is controlled by the ﬂow of ion
currents through K
+ channels, which when perturbed result
in what is known as the long QT syndrome (LQTS) (42),
potentially a life threatening disorder. The rapid delayed
rectiﬁer K+ current (IKr) is regulated by the human ERG
gene, which is downregulated in cardiac myocytes in di-
abetes, resulting in prolonged repolarization and therefore
long QT syndrome (43). The 39U T Ro ft h eE R Gm R N Ai sa
target of miR-133 (42).
Decreased cardiac expression of miR-133 has also been
associated with cardiac hypertrophy (44). In this condi-
tion, a thickening of the heart muscle results in smaller
ventricular size and reduced cardiac output, a phenome-
non observed with hypertension, the prevalence of which
is increased in subjects with diabetes. Consistent with
these observations, overexpression of miR-133 inhibits
cardiac hypertrophy whereas inhibition of miR-133 in-
duces more pronounced hypertrophy (44). Indeed, Feng
et al. (45) have demonstrated decreased miR-133a in
the diabetic mouse heart. Furthermore, in vitro exposure
of cardiomyocytes to high glucose resulted in reduced
miR-133a and more hypertrophic changes. The genes that
are dysregulated in this case are RhoA, Cdc42 and WHSC2,
all of which are known to be important in cardiac hyper-
trophy (44).
miR-320. Recent work by Wang et al. (46) identiﬁed ele-
vated miR-320 as a potential mediator of several angiogenic
factors in diabetic myocardial microvascular endothelial
cells as compared with control cells. The factors regu-
lated by this miRNA include VEGF, ﬁbroblast growth factor,
IGF-1, and IGF-1R—all of which are particularly relevant to
diabetic cardiomyopathy. Increased expression of miR-320
P. KANTHARIDIS AND ASSOCIATES
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are likely to play a role in the impaired angiogenesis ob-
served in diabetes.
miR-29. The work of van Rooij et al. (17) demonstrated
a role for miR-29 in human and mouse hearts during
myocardial infarction. Ectopic expression of miR-29b was
shown to decrease collagen expression in cardiac ﬁbro-
blasts. Conversely, miR-29 inhibitors delivered by tail vein
injection were able to decrease collagen expression not
only in the heart, but also in the liver and kidney. Whether
dysregulation of the miR-29 family members occurs in the
diabetic heart as in the kidney remains to be established.
miR-30. CTGF expression is important in the heart where
expression levels correlate with collagen levels and ﬁbro-
sis. Liu et al. (47) reported that miR-133 knockout mice
develop severe cardiac ﬁbrosis. Both miR-30 and miR-133
target CTGF for repression (48) and may be relevant since
elevated CTGF levels are seen in the context of diabetes,
including within the heart (49).
miR-21. Enhanced expression of miR-21 in the failing heart
is selectively expressed in cardiac ﬁbroblasts (50) and is
increased in association with elevated extracellular signal-
regulated kinase (ERK) signaling by downregulating the
ERK inhibitor, Spry1. The ultimate result of activated ERK
in cardiac ﬁbroblasts is elevated collagen expression. In
vivo silencing of miR-21 caused decreased ERK kinase
activity and reduced interstitial ﬁbrosis. Increased ex-
pression of miR-21 is found in the infarct zone in cardiac
ﬁbroblasts (51). Despite the importance of miR-21 in DN, it
remains to be determined how relevant this miRNA is to
complications in the diabetic heart.
WHAT DOES THE FUTURE HOLD?
Despite considerable progress in further understanding the
link between miRNAs, development, physiology, and dis-
ease, what is becoming clearer is the ever-increasing com-
plexity of the interactions between miRNAs and mediators
of signaling pathways that are relevant to diabetes and
particularly to its complications. It is becoming clearer
that a number of factors need to be taken into account
with miRNA research and that the study of individual
miRNAs, which are interesting in their own right, should
not be interpreted in isolation. While a number of miRNAs
have been associated with diabetes complications (Table 1),
the challenge remains to establish the role of these miRNAs
in clinical disease and to identify the regulatory mecha-
nisms or pathways related to miRNA expression in the
pathogenesis of the various disorders. The development
of new genetic miRNA mouse models will greatly facilitate
advances in this exciting area and help to address some of
the unanswered questions regarding the regulation of sig-
naling pathways that emanate from many of the in vitro
observations. There is also much commercial interest in
the development of technologies to block or enhance miRNA
expression in vivo as a new approach to the manage-
ment of human disease, inclu d i n gt h et r e a t m e n to fd i -
abetes complications.
Two signiﬁcant challenges remain a barrier to taking ad-
vantage of the knowledge currently gained in experimental
studies to the next stage where they can be used clinically.
In recent times, the focus has moved toward a number
of speciﬁc miRNAs that are emerging as potential thera-
peutic targets either by restoring expression or inhibition.
Chemical advances in the area of delivery of miRNA
inhibitors including cholesterol modiﬁcations and locked
nucleic acid–modiﬁed anti-miRNAs have enabled efﬁcient
delivery of these molecules to various tissues (52,53), the
stability of the inhibitors ranging up to 10 weeks in vivo
following a single injection (17). However, in terms of in
vivo delivery of miRNA mimics, huge challenges remain
because mimics have a very short half-life and chemical
modiﬁcation alters their biological properties. Much of the
literature describing such studies with mimics needs to be
carefully evaluated. Some options being investigated in-
clude viral mediated delivery of mimics. This approach has
been used in different models with a moderate degree of
success (44,54–56).
A second obstacle relates to the targeting of speciﬁc
tissues. Most approaches to date have involved nonspeciﬁc
systemic delivery. The use of adeno-associated viral sero-
types can improve speciﬁc delivery to some tissues (57).
More recent attention has turned to the development of
virally delivered tissue speciﬁc promoter driven miRNA
expression. The development of therapeutic strategies to
effectively deliver the miRNAs or inhibitors into the dis-
eased tissues is urgently needed.
Despite the challenges for miRNAs as either a therapy
or a target for new therapies, the use of miRNAs holds
much promise as a new treatment, since these molecules
are naturally occurring endogenous regulators of cell pro-
cesses that are often dysregulated in disease. With im-
proved understanding of the mechanisms whereby miRNAs
repress gene expression and the development of more se-
lective and stable mimics and inhibitors of miRNAs, this
could lead to better approaches to address the “gene ex-
pression defects” that occur in various diseases, including
diabetes complications. Where dysregulation of speciﬁc
miRNA expression is linked to disease, the development
of better targeted delivery systems is likely to lead to tai-
lored treatment of patients. With the emergence of speciﬁc
miRNAs that are common to a number of complications
such as mir-29, which is implicated in organ ﬁbrosis, the
development of a more generalized approach to treat com-
plications with the administration of a small cocktail of
miRNAs or inhibitors becomes feasible. Indeed, proﬁling
experiments to identify patterns of miRNA dysregulation
that may be common to several complications would be
au s e f u lﬁrst step in this direction.
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